Search results
Showing 16 to 30 of 65 results for diabetic foot
ID NG19/8 Question How often should people with diabetic foot problems (foot ulcers, soft tissue infections, osteomyelitis...
What is the clinical effectiveness of different dressing types in treating diabetic foot problems?
is the clinical effectiveness of different dressing types in treating diabetic foot problems? Any explanatory notes(if applicable) Source
clinical effectiveness of maggot debridement therapy in the debridement of diabetic foot ulcers? Any explanatory notes(if applicable)...
educational models and psycho-behavioural interventions in prevention of diabetic foot complications? Any explanatory notes(if...
effectiveness of negative pressure wound therapy in the treatment of diabetic foot ulcers? Any explanatory notes(if applicable) Source
educational models and psycho-behavioural interventions in prevention of diabetic foot complications? Any explanatory notes(if...
This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
NG19/1 Question Does intensive monitoring of people at risk of diabetic foot disease reduce the morbidity associated with developing the...
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13